News
Promising New Developments In AI: Innovating To Drive Efficiency And Quality In Clinical Trials
15+ hour, 44+ min ago (230+ words) Promising New Developments In AI Innovating To Drive Efficiency And Quality In Clinical Trials'Clinical Leader Promising New Developments In AI: Innovating To Drive Efficiency And Quality In Clinical Trials By Jonas Renstr'm, Director, Digital Strategy & Innovation, and Laurence Lin, Associate…...
There's A Gap In Brain Tumor Research " Here's How We Fix It
7+ hour, 44+ min ago (634+ words) Clinical Leader Guest Column | April 9, 2026 There's A Gap In Brain Tumor Research " Here's How We Fix It By Catherine Bladen, Ph. D. , tenured biochemistry researcher and scientist As a cancer researcher, I have spent my career working to deepen our mechanistic…...
Lessons Learned While Taking Glioblastoma Drug From Bench To Clinic
7+ hour, 44+ min ago (883+ words) Guest Column | April 9, 2026 A conversation between Mimi Vax CEO Mike Ciesielski, Ph. D. , and Clinical Leader Executive Editor Abby Proch About 15 years ago, Mike Ciesielski, Ph. D. , and colleagues at Roswell Park Cancer Institute in Buffalo spun off their research targeting survivin,…...
The Much-Feared FDA Form 483, Part 3
20+ hour, 59+ min ago (134+ words) Guest Column | April 8, 2026 By Robert Califf, MD This final installment offers an example of how the misperception of the 483 as a surrogate for overall quality of a firm can lead to policy errors in attempting to mitigate pricing problems with…...
Retina Clinical Trials: What Re-Acquisition In Retinal Imaging Is Really Costing Your Program
22+ hour, 38+ min ago (214+ words) Retina Clinical Trials What Re-Acquisition In Retinal Imaging Is Really Costing Your Program'Clinical Leader Retina Clinical Trials: What Re-Acquisition In Retinal Imaging Is Really Costing Your Program Retinal clinical trials often operate under the illusion that a failed OCT scan…...
Considerations For Allergic Rhinitis Trials Are Nothing To Sneeze At
1+ day, 7+ hour ago (678+ words) Guest Column | April 8, 2026 A conversation with CEO Inimmune David Burkhart, Ph. D. , and Clinical Leader Executive Editor Abby Proch The closure of GSK's Hamilton, Montana, R&D site is now 10 years in the past. And in the decade since, a team…...
Highlands Oncology Delivers World-Class Cancer Research And Care, Close To Home In Northwest Arkansas
1+ day, 7+ hour ago (199+ words) Highlands Oncology Delivers World-Class Cancer Research And Care Close To Home In Northwest Arkansas'Clinical Leader Highlands Oncology Delivers World-Class Cancer Research And Care, Close To Home In Northwest Arkansas In the evolving landscape of community oncology, providing local access to…...
Combination Therapy Dose Optimization In Oncology Trials
2+ day, 19+ hour ago (215+ words) Clinical Leader Combination Therapy Dose Optimization In Oncology Trials By Jeffrey Hodge, MS, Vice President Early Phase Oncology, Hematology-Oncology Center of Excellence, David Alsadius, MD, Ph D, Senior Medical Director, Solid Tumor Lead, Hematology-Oncology Center of Excellence, Jennifer Underwood, MSc,…...
Google News
3+ day, 7+ hour ago (17+ words) Why Clinical And Commercial Development Must Be Integrated Fully And Early For FDA And Reimbursement Success'Clinical Leader...
ICON And Medable Drive 85% e Consent Adoption In U. S. Menopause Study
3+ day, 3+ hour ago (205+ words) Clinical Leader ICON And Medable Drive 85% e Consent Adoption In U. S. Menopause Study Achieving strong electronic consent adoption can be difficult in complex clinical trials " especially those with frequent assessments and diverse participant populations. A U. S. -based menopause study demonstrates how a…...